CSIMarket
 


Intellia Therapeutics Inc   (NTLA)
Other Ticker:  
 


Intellia Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics



NTLA Gross Profit Margin (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Revenue Change -9.6 % -3.11 % 12.03 % 5.59 % 84.15 %
Seq. Revenue Change -11.78 % 7.84 % -7.12 % 2.31 % -5.45 %
Revenue In Millions $11.99 $13.59 $12.61 $13.57 $13.27
Gross Profit Margin - - - - -
Gross Profit Margin Total Ranking # 699 # 781 # 832 # 1190 # 862
Gross Profit In Millions $11.99 $13.59 $12.61 $13.57 $13.27
Y / Y Gross Profit Change - - - - -
Seq. Gross Profit Change - - - - -


Commenting Third Quarter 2023 Gross Profit Margin
Intellia Therapeutics Inc experienced contraction in Gross Profit by -11.78 % to $12 millions and Revenue by -11.78 %, while Gross Profit Margin fell to 100 % a new company low.

Observing third quarter 2023 results within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 699, from total ranking in previous quarter at 781.
Learn about Gross Margin
NTLA's Gross Profit Margin third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 4
Healthcare Sector # 202
Overall # 695

Gross Profit Margin Statistics
High Average Low
195.4 % 103.53 % 100 %
(Dec 31 2019)   (Sep 30 2023)




Other Gross Profit Margin Profitability Ratios
NTLA's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NTLA's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NTLA's Competitors
Gross Profit Margin Profit Margin for Intellia Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for NTLA's Customers

You may also want to know
NTLA's Annual Growth Rates NTLA's Profitability Ratios NTLA's Asset Turnover Ratio NTLA's Dividend Growth
NTLA's Roe NTLA's Valuation Ratios NTLA's Financial Strength Ratios NTLA's Gross Profit Growth
NTLA's Roa NTLA's Inventory Turnover Ratio NTLA's Growth Rates NTLA's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginSep 30 2023 MRQ Gross ProfitSep 30 2023 MRQ Revenue
Cardio Diagnostics Holdings Inc   100.00 %$ 0.010 $ 0.010 
Celldex Therapeutics inc   100.00 %$ 1.517 $ 1.517 
Intellia Therapeutics Inc   100.00 %$ 11.992 $ 11.992 
Volitionrx Limited  100.00 %$ 0.165 $ 0.165 
Myriad Genetics Inc   69.98 %$ 134.300 $ 191.900 
Lantheus Holdings Inc   62.69 %$ 199.951 $ 318.951 
Idexx Laboratories Inc  59.89 %$ 547.982 $ 914.982 
Aspira Women s Health Inc   58.95 %$ 1.307 $ 2.217 
Oncocyte Corporation  57.81 %$ 0.248 $ 0.429 
Neogen Corporation  51.04 %$ 116.761 $ 228.761 
Quidelortho Corp  49.48 %$ 368.100 $ 744.000 
Immucell Corp  24.05 %$ 1.267 $ 5.267 
Biomerica Inc   24.05 %$ 0.412 $ 1.713 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com